Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis

• DOI: 10.1186/s12876-023-02938-6
• Publication Date: 2023-10-06T08:02:40Z
• Authors: Xinqiao Chu; Yaning Biao; Chengjiang Liu; Yixin Zhang; Chenxu Liu; Ji-zheng Ma; Yufeng Guo; Yaru Gu
• Keywords: Vedolizumab; Discontinuation

Abstract Background Therapeutic options for ulcerative colitis (UC) have increased since the introduction of biologics a few decades ago. Due to wide range available, physicians difficulty in selecting and do not know how balance best drug between clinical efficacy safety. This study aimed compare safety treating colitis. Methods In this study, eight electronic databases (PubMed, Web Science, Cochrane, Embase, Sinomed, China National Knowledge Infrastructure, Chongqing VIP Information, WanFang Data) were searched collect eligible studies without language restrictions. Retrieved 1 June 2023, from inception. All articles included mesh analysis are randomised controlled trials (RCTs). The inclusion drugs each outcome was ranked using curved surface under cumulative ranking (SUCRA). Higher SUCRA scores associated with better outcomes, whereas lower has registered PROSPERO, CRD42023389483. Results Induction Therapy: Among biologic therapies evaluated induction therapy, vedolizumab demonstrated highest achieving remission (OR vs daclizumab, 9.09; 95% CI, 1.01–81.61; 94.1) response. Guselkumab showed lowest risk recurrence UC (SUCRA 94.9%), adverse events resulting treatment discontinuation 94.8%), serious infections 78.0%). Maintenance For maintenance maintaining mesalazine 4.36; 1.65–11.49; 89.7) endoscopic improvement 92.6). Infliximab 92.6%). Ustekinumab had 92.9%), 91.3%), 67.6%). Conclusion Our network meta-analysis suggests that is most effective therapy inducing patients. shows promise reducing during therapy. improving outcomes appears favorable profile. These findings provide valuable insights clinicians appropriate